Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 11/20 | 0.46 |
| ▸ | CNR2 | P34972 | 9/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16050682 | 0.87 | GPR84 (0.66) | PTGS2GPR84HSP90AB1CYP4F2CYP4A11 | |
| SCHEMBL14420070 | 0.83 | HSP90AB1 (0.55) | HSP90AB1GLSCYP4F2CYP4A11 | |
| SCHEMBL348963 | 0.83 | HSP90AB1 (0.62) | HSP90AB1GLSCYP4F2CYP4A11 | |
| SCHEMBL1628911 | 0.81 | HSP90AB1 (0.67) | PTGS2GPR84HSP90AB1CNR1CNR2 | |
| SCHEMBL14420121 | 0.79 | SLC7A5 (0.55) | HSP90AB1CYP4F2CYP4A11 | |
| SCHEMBL9279920 | 0.79 | PTGS2 (0.67) | PTGS2CNR1CNR2 | |
| SCHEMBL16955432 | 0.78 | PTGS2 (0.62) | PTGS2GPR84CNR1CNR2 | |
| SCHEMBL27473665 | 0.78 | CYP4F2 (0.68) | CYP4F2CYP4A11 | |
| SCHEMBL14626264 | 0.78 | HSP90AB1 (0.51) | HSP90AB1CYP4F2CYP4A11 | |
| SCHEMBL21891794 | 0.77 | HSP90AB1 (0.75) | HSP90AB1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | TLR7, CCR8, TLR8 | PTGS2 1288/4885GPR84 118/4885HSP90AB1 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.